Safety evaluation of monophosphoryl lipid a (MPL): An immunostimulatory adjuvant

被引:71
作者
Baldrick, P
Richardson, D
Elliott, G
Wheeler, AW
机构
[1] Covance Labs Ltd, Harrogate HG3 1PY, N Yorkshire, England
[2] Allergy Therapeut Ltd, Worthing BN14 8SA, W Sussex, England
[3] Corixa Corp, Hamilton, MT USA
关键词
MPL; adjuvant; allergy vaccines; immunostimulatory; toxicity assessment;
D O I
10.1006/rtph.2002.1541
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
Animal models have shown the potential use of monophosphoryl lipid A (MPL(R)), a detoxified bacterial lipopolysaccharide, as a vaccine adjuvant. Immunostimulatory activity with diverse effects on the cellular elements of the immune system has been demonstrated and a range of vaccines incorporating MPL, including allergy vaccines, are currently under clinical evaluation. A series of preclinical safety investigations was performed to support clinical use of MPL as used in allergy vaccines and comprised cardiovascular/respiratory assessment in dog (up to 100 mug/kg/day); repeat-dose toxicity in rat, rabbit, and dog (up to 2500 and 1200 mug/kg/day in the rat and dog, respectively); reproduction toxicity in rat and rabbit (up to 100 mug/kg/day); and genotoxicity studies. Overall, repeat-dose toxicity studies in the rat and dog showed expected immunostimulatory effects and/or signs of toxicity associated with overstimulation of the immune system (notably increased spleen weight and white blood cell values). Studies in the rabbit with weekly doses of MPL produced no effects. MPL was shown to have no adverse effects on cardiovascular/respiratory function, reproduction, and genotoxicity. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:398 / 413
页数:16
相关论文
共 50 条
[1]   LIPOPOLYSACCHARIDE, LIPID-A, AND LIPOSOMES CONTAINING LIPID-A AS IMMUNOLOGICAL ADJUVANTS [J].
ALVING, CR .
IMMUNOBIOLOGY, 1993, 187 (3-5) :430-446
[2]   ABILITY OF MONOPHOSPHORYL LIPID A TO AUGMENT THE ANTIBODY-RESPONSE OF YOUNG MICE [J].
BAKER, PJ ;
HIERNAUX, JR ;
FAUNTLEROY, MB ;
STASHAK, PW ;
PRESCOTT, B ;
CANTRELL, JL ;
RUDBACH, JA .
INFECTION AND IMMUNITY, 1988, 56 (12) :3064-3066
[3]   INACTIVATION OF SUPPRESSOR T-CELL ACTIVITY BY NONTOXIC MONOPHOSPHORYL LIPID-A [J].
BAKER, PJ ;
HIERNAUX, JR ;
FAUNTLEROY, MB ;
PRESCOTT, B ;
CANTRELL, JL ;
RUDBACH, JA .
INFECTION AND IMMUNITY, 1988, 56 (05) :1076-1083
[4]   Pharmaceutical excipient development: The need for preclinical guidance [J].
Baldrick, P .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2000, 32 (02) :210-218
[5]   Effective adjuvants for the induction of antigen-specific delayed type hypersensitivity [J].
Baldridge, JR ;
Ward, JR .
VACCINE, 1997, 15 (04) :395-401
[6]   Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration [J].
Baldridge, JR ;
Yorgensen, Y ;
Ward, JR ;
Ulrich, JT .
VACCINE, 2000, 18 (22) :2416-2425
[7]   Application of immunologic methods in clinical trials [J].
Buhles, WC .
TOXICOLOGY, 1998, 129 (01) :73-89
[8]   EFFECT OF MONOPHOSPHORYL LIPID-A ON THE INVITRO FUNCTION OF PERITONEAL LEUKOCYTES FROM UREMIC PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS [J].
CAROZZI, S ;
SALIT, M ;
CANTALUPPI, A ;
NASINI, MG ;
BAROCCI, S ;
CANTARELLA, S ;
LAMPERI, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (08) :1748-1753
[9]   Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen [J].
Childers, NK ;
Miller, KL ;
Tong, G ;
Llarena, JC ;
Greenway, T ;
Ulrich, JT ;
Michalek, SM .
INFECTION AND IMMUNITY, 2000, 68 (10) :5509-5516
[10]   CRYPTOCOCCUS-NEOFORMANS SEROTYPE-A GLUCURONOXYLOMANNAN-PROTEIN CONJUGATE VACCINES - SYNTHESIS, CHARACTERIZATION, AND IMMUNOGENICITY [J].
DEVI, SJN ;
SCHNEERSON, R ;
EGAN, W ;
ULRICH, TJ ;
BRYLA, D ;
ROBBINS, JB ;
BENNETT, JE .
INFECTION AND IMMUNITY, 1991, 59 (10) :3700-3707